CoChat

Rosiglitazone Decreases Bone Mass and Bone Marrow Fat

Harsløf, Torben, Wamberg, Louise, Møller, Louise, Stødkilde-Jørgensen, Hans, Ringgaard, Steffen, Pedersen, Steen B., Langdahl, Bente L. · 2011 · The Journal of Clinical Endocrinology & Metabolism
Cited by 57

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

CONTEXT: Activation of peroxisome proliferator-activated receptor-γ is believed to promote adipocyte development from mesenchymal stem cells in the bone marrow at the expense of osteoblasts, leading to decreased bone mineral density (BMD) and increased marrow fat. OBJECTIVE: The objective of the study was to examine the effect of the peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, on BMD assessed by dual-energy x-ray absorptiometry in 53 healthy postmenopausal women and spine bone marrow fat assessed by magnetic resonance imaging proton spectroscopy. DESIGN: This was a 14-wk prospective, double-blind, randomized, placebo-controlled trial. SETTING: The study was conducted in the general community. PATIENTS: Fifty-three healthy postmenopausal women participated in the study. INTERVENTION: Intervention included rosiglitazone tablets of 8 mg/d. MAIN OUTCOME MEASURES: The primary end point was a change in BMD. RESULTS: At the femoral neck, BMD decreased by 1.34 ± 0.60% (mean ± sem) in the rosiglitazone group, whereas BMD increased by 0.28 ± 0.56% in the placebo group (P = 0.055). At the lumbar spine, BMD decreased by 1.03 ± 0.34% in the rosiglitazone group and 0.42 ± 0.35% in the placebo group (P = 0.22). The bone resorption marker carboxy-terminal telopeptide increased by 20.4 ± 7.7% (mean ± sem) in the rosiglitazone group and decreased by 7.1 ± 4.7% in the placebo group (P = 0.003). Spine fat decreased by 13.5 ± 5.5% (mean ± sem) in the rosiglitazone group and increased by 6.8 ± 7.4% in the placebo group (P = 0.056). CONCLUSIONS: Contrary to what was expected, spine fat decreased during rosiglitazone treatment. Furthermore, rosiglitazone treatment resulted in uncoupling of bone resorption and formation leading to bone loss. Our data suggest that the bone marrow osteoblast-adipocyte relationship is more complex than was assumed and that the two cell types can be independently affected.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2010-2077

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 57

Metadata

Authors
Harsløf, T., Wamberg, L., Møller, L., Stødkilde-Jørgensen, H., Ringgaard, S., Pedersen, S. B., & Langdahl, B. L.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2011-05
Volume
96
Issue
5
Pages
1541-1548
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2086049599
Cited by
57
References
2
FWCI
7.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rosiglitazone Decreases Bone Mass and Bone Marrow Fat. https://app.cochat.ai/papers/10.1210/jc.2010-2077
The paper
Harsløf, T., Wamberg, L., Møller, L., Stødkilde-Jørgensen, H., Ringgaard, S., Pedersen, S. B., & Langdahl, B. L. (2011). Rosiglitazone Decreases Bone Mass and Bone Marrow Fat. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-2077

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.